Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Leslie on the Need for Clinical Trials to Address Unmet Needs in MCL

September 16th 2020

Lori A. Leslie, MD, discusses the importance of clinical trials in finding novel, up-front therapy options for patients with mantle cell lymphoma.

Dr. Visco on the Utility of Bendamustine in MCL

September 15th 2020

Carlo Visco, MD, discusses the utility of bendamustine-based regimens in mantle cell lymphoma.

Dr. Leslie on the Role of Zanubrutinib in MCL

September 14th 2020

Lori A. Leslie, MD, discusses the role of zanubrutinib in mantle cell lymphoma.

Dr. Ghosh on Approved BTK Inhibitors in B-Cell Malignancies

September 14th 2020

Nilanjan Ghosh, MD, PhD, discusses approved BTK inhibitors in B-cell malignancies.

SYMPATICO Evaluates Frontline Ibrutinib and Venetoclax Combo in MCL

September 14th 2020

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

Dr. Visco on the Utility of Cytarabine in MCL

September 10th 2020

Carlo Visco, MD, discusses the utility of cytarabine in relapsed/refractory mantle cell lymphoma.

Dr. Visco on the Rationale for the MANTLE-FIRST Trial in R/R MCL

September 9th 2020

Carlo Visco, MD, discusses the rationale for the international, retrospective MANTLE-FIRST trial in relapsed/refractory mantle cell lymphoma.

Dr. Leslie on Emerging Therapies in MCL

September 3rd 2020

Lori A. Leslie, MD, lymphoma attending, discusses emerging therapies in mantle cell lymphoma.

Building on Current Understandings of BTK Inhibition in CLL, MCL

August 19th 2020

Nilanjan Ghosh, MD, PhD, discusses the role of BTK inhibitors in B-cell malignancies and ongoing research with each agent.

Dr. Ghosh on Differences Among Available BTK Inhibitors in B-Cell Malignancies

August 18th 2020

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Dr. Ghosh on Global Trials With Zanubrutinib in MCL and NHL

August 14th 2020

Nilanjan Ghosh, MD, PhD, discusses global trials examining zanubrutinib in mantle cell lymphoma and non-Hodgkin lymphoma.

MCL Treatment Armamentarium Transforms With BTK Inhibitors, CAR T-Cell Addition

August 13th 2020

Peter Martin, MD, provides an overview of what the current MCL treatment paradigm looks like as well as areas of future exploration and debate.

Dr. Davids on Remaining Questions With Umbralisib/Ibrutinib in CLL and MCL

August 10th 2020

Matthew S. Davids, MD, MMSc, discusses remaining questions with umbralisib plus ibrutinib in chronic lymphocytic leukemia and mantle cell lymphoma.

John Theurer Cancer Center Investigators Participated in ZUMA-2 Study Leading to FDA Approval of First CAR T-Cell Therapy for Recurrent/Persistent Mantle Cell Lymphoma

August 4th 2020

Investigators from John Theurer Cancer Center participated in the pivotal ZUMA-2 clinical trial, which assessed the safety and effectiveness of brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma.

Dr. Wang on the Safety Profile of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

Michael Wang, MD, discusses the safety profile of the CAR T-cell therapy brexucabtagene autoleucel in relapsed/refractory mantle cell lymphoma.

FDA Approval Insights: Brexucabtagene Autoleucel in Relapsed/Refractory MCL

August 3rd 2020

In our exclusive interview, Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Wang Welcomes the FDA Approval of Brexucabtagene Autoleucel in MCL

July 30th 2020

Michael Wang, MD, discusses the FDA approval of brexucabtagene autoleucel in mantle cell lymphoma and ongoing research aimed at optimizing the safety and persistence of the product.

Dr. Roué on the Rationale for Evaluating TG-1701 in Ibrutinib-Resistant MCL Models

July 24th 2020

Gaël Roué, PhD, discusses the rationale to evaluate the novel irreversible BTK inhibitor TG-1701 in preclinical models of ibrutinib-resistant mantle cell lymphoma.

Dr. Wang on the FDA Approval of Brexucabtagene Autoleucel in MCL

July 24th 2020

Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the FDA approval of brexucabtagene autoleucel (Tecartus; formerly KTE-X19) in mantle cell lymphoma (MCL).

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory MCL

July 24th 2020

The FDA has approved the CAR T-cell therapy brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory mantle cell lymphoma.